Molecular targeted therapies and chemotherapy in malignant gliomas

Current Opinion in Oncology

Volumn 19, Issue 6, 2007, Pages 598-605

  Brandsma, Dieta ^a   Van Den Bent, Martin J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Malignant glioma; Targeted therapy; Temozolomide; Vascular endothelial growth factor

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AP 23573; BEVACIZUMAB; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LAPATANIB; LOMUSTINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCARBAZINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; TYCERB; VASCULOTROPIN RECEPTOR; VATALANIB; VINCRISTINE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL SURVIVAL; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; DISEASE FREE INTERVAL; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR THERAPY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; UPREGULATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; OLIGODENDROGLIOMA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 34848819103     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f0313b     Document Type: Review

References (74)

1. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40:51-55.
2. Davis FG, McCarthy BJ, Freels S, et al. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 1999; 85:485-491.
3. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 2003; 3:595-614.
4. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004; 4:105-128.
5. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
7. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide- mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006; 12:4738-4746. This in-vivo study showsthe synergistic effect ofcombined chemo-irradiation inGBM cell lines and xenografts with MGMT promoter gene methylation. It offers an explanation for the improved outcome of patients treated with combined chemoirradiation with TMZ for GBM with MGMT promoter gene methylation.
8. Möllemann M, Wolter M, Felsberg J, et al. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2004; 113:379-385.
9. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005; 11:5167-5174.
10. Chang SM, Prados MD, Yung WKA, et al. Phase II study of neoadjuvant 1, 3-bis(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer 2004; 100:1712-1716.
11. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24:4412-4417.
12. Gerber DE, Grossman SA, ZeltzmanM, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007; 9:47-52. The study emphasizes the potential toxicity of combined chemo-irradiation with TMZ, with severe myelotoxicity in 20% of cases and persistent myelosuppression in 4% of cases.
13. De Wit MCY, De Bruin HG, Eijkenboom WMH, et al. Immediate postradiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63:535-537.
14. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82:81-83. This study showed a high incidence (14%) of early radionecrosis after concomitant chemo-irradiation in GBM, which in fact were half of the patients that were operated upon for an early recurrence. The clinical importance of this observation is the need to consider second surgery in patients with progressive lesions shortly after radiotherapy, especially if clinically symptomatic.
15. Taal W, Brandsma D, De Bruin HG, et al. The incidence of pseudoprogression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide [abstract]. J Clin Oncol 2007; 25 (18S):2009.
16. Leimgruber A, Osterman S, Yeon EJ, et al. Perfusion and diffusion MRI of glioblastoma progression in a four year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 2006; 64:869-875.
17. ••], two randomized studies showing that earlyPCV chemotherapy with radiotherapy improves PFS, but not overall survival, and the much better outcome of 1p/19q codeleted oligodendroglial tumors.
18. ••], two randomized studies showing that earlyPCV chemotherapy with radiotherapy improves PFS, but not overall survival, and the much better outcome of 1p/19q codeleted oligodendroglial tumors.
19. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
20. Van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97:1276-1284.
21. Bauman GS, Ino Y, Yeki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys 2000; 48:825-830.
22. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 2000; 18:636-645.
23. •], research that identified 1p/19q codeletion to be mediated by a balanced translocation.
24. •], research that identified 1p/19q codeletion to be mediated by a balanced translocation.
25. •], established the correlation between 1p/19q loss and response to temozolomide in oligodendroglial tumors.
26. •], established the correlation between 1p/19q loss and response to temozolomide in oligodendroglial tumors.
27. Triebels V, Taphoorn MJB, Brandes AA, et al. Response to 2nd line PCV chemotherapy in recurrent oligodendroglioma after 1st line temozolomide. Neurology 2004; 63:904-906.
28. Van den Bent MJ, Chinot O, Boogerd W, et al. Second line chemotherapy with Temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003; 14:599-602.
29. 6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106:1759-1765.
30. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004; 3:430-446.
31. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
32. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677.
33. Kapoor GS, O'Rourke DM. Mitogenic signaling cascades in glial tumors. Neurosurgery 2003; 52:1425-1434.
34. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997; 57:4183-4186.
35. Stambolic V, Suzuki A, De la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
36. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999; 253:117-130.
37. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359:845-848.
38. Chaudhry IH, O'Donovan DG, Brenchley PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001; 39:409-415.
39. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006; 11:152-164.
40. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64:6892-6899.
41. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217-223.
42. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992; 89:4309-4313.
43. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272:2927-2935.
44. Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-1387.
45. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004; 63:700-707.
46. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006; 8:67-78.
47. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006; 12:860-868.
48. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
49. Uhm JH, Ballman KV, Giannini C, et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma [abstract]. J Clin Oncol 2004; 22 (14S):1505.
50. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs [abstract]. J Clin Oncol 2004; 22 (14S):1502.
51. Vogelbaum MA, Peereboom DM, Stevens G, et al. Phase II study of erlotinib single agent therapy in recurrent glioblastoma multiforme. Eur J Cancer Suppl 2005; 3:135.
52. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005; 11:7841-7850.
53. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
54. Van den Bent MJ, Brandes A, Rampling R, et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 [abstract]. J Clin Oncol 2007; 25 (18S):2005.
55. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
56. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004; 22:1926-1933.
57. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98:10314-10319.
58. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23:5294-5304.
59. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005; 23:357-361.
60. Nguyen TD, Lassman AB, Lis E, et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 2006; 24 (18S):1507.
61. Ostman A. PDGF receptors - mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15:275-286.
62. Lokker NA, Sullivan CM, Hollenbach SJ, et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002; 62:3729-3735.
63. Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003; 22:722-733.
64. Raymond E, Brandes A, Van Oosterom A, et al. Multicenter phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG Intergroup Study [abstract]. J Clin Oncol 2004; 22 (14S):1501.
65. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-4907.
66. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005; 16:1702-1708.
67. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23:9359-9368.
68. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007; 83:53-60.
69. Conrad C, Friedman H, Reardon D, et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2004; 22 (14S):1512.
70. Reardon D, Friedman H, Yung WKA, et al. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2004; 22 (14S):1513.
71. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-1259. Results of the first phase II study showing high response rates and improved survival for the combination of bevacizumab and irinotecan in recurrent gliomas.
72. Batchelor TT, Sorensen AG, Di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. Phase II study with extensive neuro-imaging research indicating a strong antiedema effect of AZD2171 in glioblastoma patients, with an interesting 6-month PFS showing that antiangiogenic agents are indeed likely to play a major role in the management of high grade gliomas.
73. Cloughesy TF, Kuhn J, Robins HI, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2005; 23:6647-6656.
74. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006; 24:3651-3656.